1 / 10The Covishield vaccine produced more antibodies than Covaxin, according to a preliminary study by Coronavirus Vaccine-induced Antibody Titre (COVAT) involving healthcare workers (HCW) who have received both doses of either of the two vaccines.2 / 10Seropositivity rates to anti-spike antibody were significantly higher in Covishield recipients compared to Covaxin after the first dose, the study claimed.3 / 10The study is a preprint and has not been peer-reviewed, so should not be used to guide clinical practice.4 / 10It said that both vaccines - Covishield and Covaxin - elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.5 / 10'Amongst the 552 HCW (325 Male, 227 Female), 456 and 96 received the first dose of Covishield and Covaxin respectively.6 / 10Overall, 79.3 per cent showed seropositivity after the first dose.7 / 10Responder rate and median (IQR) rise in anti-spike antibody were significantly higher in Covishield vs Covaxin recipient (86.8 vs. 43.8 per cent; 61.5 vs 6 AU/ml; both p<0.001),' the study said.8 / 10The study involved those healthcare workers who have been administered either of the two vaccines, Covishield and Covaxin, and are with or without past history of SARS-CoV-2 infection.9 / 10'This ongoing, Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without past history of SARS-CoV-2 infection.10 / 10SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four timepoints between 21 days or more after the first dose to 6 months after the second dose,' the study said.